¡Ya estamos en ! Descubre más

Rhythm Pharmaceuticals

RYTM

Capitalización de mercado USD 5933 M

86.17 USD

-1.80

2.05%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

85.00

-1.17

1.36%

1 día

-2.05%

5 días

-5.36%

1 mes

-12.08%

3 meses

-18.78%

6 meses

-2.2%

En lo que va del año

-17.94%

1 año

-22.5%

5 años

689.83%

10 años

187.23%

Acerca de: Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Empleados: 414

Atención médica Biotecnología

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 30.4%

Neutral 65.2%

Negativo 4.3%

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan for patients living with acquired hypothalamic obesity --

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

Zacks Investment Research

Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know

Rhythm Pharmaceuticals (RYTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) breached their fiduciary duties to shareholders.

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Health Canada has approved IMCIVREE® (setmelanotide) for the additional indication of weight management in adult and pediatric patients 4 years of age and older with acquired hypothalamic obesity (HO).

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France – -- Phase 3 analyses demonstrated improvements across multiple cardiometabolic risk indices with setmelanotide in acquired HO -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced Rhythm and its collaborators will present three posters and three oral presentations relating to the company's work in rare melanocortin-4 receptor (MC4R) pathway diseases at the 64th Annual European Society for Paediatric Endocrinology (ESPE) Meeting taking place September 8-10 in Marseille, France.

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

The Motley Fool

Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can

Rhythm Pharmaceuticals develops medicines for rare forms of obesity. The company has little competition in its target market.

Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can

Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise

Rhythm Pharmaceuticals is transitioning from a single rare disease drug to a broad MC4R therapeutic franchise, leveraging multiple formulations for market segmentation. IMCIVREE's AHO approval and over 400 patient start forms signal robust demand, with a scalable commercial model targeting endocrinologists and neuro-oncologists. RYTM's pipeline—daily, weekly, and oral MC4R agonists—aims to preempt competition and expand reach, while strong gross margins offer operating leverage.

Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the appointment of Manher “AJ” Joshi, M.D., as Chief Medical Officer, effective August 17.

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™